Abstract
ERBB family receptor tyrosine kinases are overexpressed in a significant subset of breast cancers. One of these receptors, HER2/neu, or ErbB-2, is the target for a new rational therapeutic antibody, Herceptin. Other inhibitors that target this receptor, and another family member, the epidermal growth factor (EGF) receptor, are moving into clinical trials. Both of these receptors are sometimes overexpressed in breast cancer, and still subject to regulation by hormones and other physiological regulators. Optimal use of therapeutics targeting these receptors will require consideration of the several modes of regulation of these receptors and their interactions with steroid receptors.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Biomarkers / analysis
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics
-
Breast Neoplasms / metabolism*
-
Epidermal Growth Factor / genetics
-
Epidermal Growth Factor / metabolism
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / drug effects*
-
ErbB Receptors / genetics*
-
Female
-
Gene Amplification
-
Gene Expression Regulation, Developmental
-
Gene Expression Regulation, Neoplastic
-
Genes, erbB / genetics
-
Humans
-
Protein-Tyrosine Kinases / genetics*
-
Protein-Tyrosine Kinases / metabolism*
-
Receptor, ErbB-2 / drug effects
-
Receptor, ErbB-2 / metabolism*
-
Signal Transduction*
-
Transcriptional Activation
-
Transforming Growth Factors / genetics
-
Transforming Growth Factors / metabolism
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Biomarkers
-
Epidermal Growth Factor
-
Transforming Growth Factors
-
ErbB Receptors
-
Protein-Tyrosine Kinases
-
Receptor, ErbB-2
-
Trastuzumab